What Is Radiesse? Calcium Hydroxyapatite and Collagen

The shortest answer to what is Radiesse is this: it is a fundamentally different product from a hyaluronic acid filler. It may come in a similar syringe and go in through a similar needle — but its contents, its behaviour in tissue, and the options you have if something goes wrong are all different.

Deciding without knowing that difference is not a good idea. In this article I explain what calcium hydroxyapatite is, how much of the "it builds collagen" claim the science actually supports, how long it lasts, and why it cannot be dissolved — drawing on four current sources.

What is Radiesse made of?

Radiesse is the trade name of a filler containing calcium hydroxyapatite (CaHA). Calcium hydroxyapatite is a mineral also found in bone tissue, but the form used in fillers is manufactured synthetically.

It has two components: micron-sized synthetic calcium hydroxyapatite microspheres, and a gel that carries them. In the source study, the Radiesse carrier gel is described as a mixture of glycerin, sodium carboxymethylcellulose and sterile water.

This structure gives the product a dual action:

• Immediate volume — the fullness that comes from the carrier gel right after injection.
• Delayed, longer-lasting effect — stimulation of new collagen production around the microspheres.

Because of that second effect, CaHA is described in the literature as a biostimulator. And this is exactly where care is needed.

Does Radiesse really build collagen? How true is "regenerative"?

That it stimulates collagen production is correct. But marketing that as "regeneration" is a point a number of clinicians in the field object to.

A commentary published in Aesthetic Surgery Journal, endorsed by more than 30 plastic surgeons, draws the distinction plainly:

• Regeneration: complete restoration of damaged tissue to its original structure and function, without scar formation.
• Repair: healing that proceeds by forming scar tissue, which does not fully reproduce the architecture and function of the original tissue.

According to the authors, CaHA behaves as a biocompatible scaffold that induces a controlled fibrous response. The microspheres stimulate dermal fibroblasts, and new collagen fibres are synthesised around the injected material. This contributes to aesthetic improvement — but in the authors' words it should be classified not as "regenerative" but, more precisely, as reparative.

The type of collagen formed supports that reading. Histological studies have shown that CaHA stimulates production of Type I and Type III collagen. Type III is characteristic of the early phases of scarring and is more elastic; Type I is the main component of mature skin and of dense scar tissue. The authors note that the formation of both is a sign of repair and remodelling, not of scar-free restoration of the original dermal matrix.

The same commentary observes that "biostimulation" has no precise, universally accepted scientific definition either. The example given is striking: the fibrous capsule that forms around a breast implant also involves collagen synthesis and fibroblast activation — and nobody calls that regeneration.

None of this means Radiesse does not work. It means you should set your expectation around "support and fullness in the tissue", not "my skin will be renewed". That is the authors' own conclusion: the distinction matters centrally for managing patient expectations properly.

How long does Radiesse last?

A comprehensive 2026 review classes CaHA fillers as semipermanent and reports that the effect lasts around 12–18 months.

But "12–18 months" and "the day-one look for 12–18 months" are not the same thing. A 2025 systematic review of HA and CaHA used together (19 studies: 13 human, 2 in vitro, 4 animal) found that aesthetic improvement was sustained for up to six months, after which a slight decline began to appear. The same trend showed in patient satisfaction.

In practice: the best result is in the early months and it softens over time. Reading that six-month dip as "the product failed" would be wrong — it is the expected course.

What is the most important difference from hyaluronic acid filler?

There is one answer to this, and it is the single most important thing in this article:

Calcium hydroxyapatite cannot be dissolved by any readily available enzyme such as hyaluronidase.

The greatest safety advantage of hyaluronic acid fillers is that they are reversible: if the result is not liked, or a complication develops, they can be broken down with hyaluronidase. With CaHA that option does not exist.

The 2026 review's conclusion is clear: because there is no direct reversal agent, managing CaHA-related complications relies far more heavily on prevention, early detection and supportive care.

For a patient this means: a CaHA decision commits you more than a hyaluronic acid decision does. I set out our approach to hyaluronic acid fillers separately in the midface filler article.

Where is Radiesse used, and where is it not?

The review lists the essentials of a preventive approach: appropriate patient selection, deep injection planes, conservative volumes, and skilled application.

Placement must not be superficial. Because the product is opaque, superficial placement can leave a whitish, chalky appearance under the skin, which is why deep subdermal or supraperiosteal (on the bone) placement is recommended.

The areas to avoid are named explicitly: around the mouth (perioral) and around the eyes (periorbital). The review reports that the perioral region is particularly susceptible, with unacceptably high rates of firm nodules described there.

That answers a question patients ask often: Radiesse is not used for lip filler. Hyaluronic acid is the product of choice in the lips — I set out why, and how it is done, in the lip filler article.

What is the most common problem?

According to the review, nodule formation is the most frequently reported complication with CaHA. Among patients who develop palpable nodules, the majority are self-limiting and asymptomatic.

The cause is the particulate nature of the product and placement in too superficial a plane. When product is placed in highly mobile regions or is not sufficiently distributed within the tissue, microspheres can cluster or trigger focal collagen overproduction, producing localised firmness.

The good news: these nodules are usually non-tender lumps noticeable only on palpation, and they often soften over time as the carrier gel is resorbed and collagen remodels. Less commonly they become inflamed weeks to months later, with redness and tenderness.

Because dissolving is not an option, management is mechanical: for asymptomatic, invisible nodules, watchful waiting is usually right. For visible or bothersome ones, needle puncture, saline dispersion and massage are used. Ultrasound is a real advantage here — CaHA gives a strong echo, so the position and depth of a deposit can be mapped precisely.

What do the clinical studies show?

In a prospective study published in 2025, two different CaHA products were compared in 30 patients (28 women, 2 men; mean age 49) by treating one side of the face with each. The treated area was in front of the ear and the lower-medial and posterior face; the perioral, periorbital and forehead regions were deliberately excluded.

• Both patients and physicians reported improvement: the most common patient rating at days 60 and 120 was "improved", and the most common physician rating at day 120 was "very improved".
• On ultrasound, skin thickness increased, skin retraction time shortened (a marker of elasticity) and water loss through the skin decreased. There was no statistically significant difference between the two products (p = 0.29; 0.28; 0.83).
• The complaints most often recorded in patient diaries were pain (24 of 30 patients), swelling (15), hardening (11), redness (9), palpable lumps (8), bruising (7) and colour change (4).
• All of these resolved by day 30 after the procedure at the latest.

The study's limits should be stated: it was single-centre, unblinded and involved 30 patients, and the findings are specific to the area treated — they cannot be generalised to the whole face.

Who is Radiesse not suitable for?

This section is not from the source papers; it is a summary of my clinical practice:

• Patients who are undecided. A product that cannot be dissolved does not suit a "let's try it and reverse it if not" approach. If there is hesitation, starting with hyaluronic acid is the better path.
• Patients wanting volume in thin, mobile areas. The lips and the eye area are not this product's territory.
• Patients expecting skin-surface improvements. Pigmentation, pores and surface texture need different approaches.
• Patients expecting marked laxity to be corrected. In advanced laxity the support achievable by injection is limited; sometimes the right answer is a surgical assessment.

Regulatory approval — and which areas a product is approved for — varies from country to country. You are entitled to ask which product will be used and what its local approval status is before treatment.

Frequently asked questions

What is Radiesse? It is a filler in which synthetic calcium hydroxyapatite microspheres are suspended in a carrier gel. It gives both immediate volume and stimulates new collagen production around the microspheres. It is a different product from hyaluronic acid fillers.

Does Radiesse really build collagen? It has been shown to stimulate collagen production, and histological studies report the formation of Type I and Type III collagen. But according to a commentary in Aesthetic Surgery Journal, that process should be described not as "regeneration" but more accurately as repair.

How long does Radiesse last? Reviews report an effect lasting around 12–18 months. Aesthetic improvement has been observed to hold for up to six months, after which a slight decline begins.

Can Radiesse be dissolved? No. Calcium hydroxyapatite cannot be broken down by a readily available enzyme such as hyaluronidase. This is its most important difference from hyaluronic acid fillers and must be weighed when deciding.

Is Radiesse used as a lip filler? No. The review reports unacceptably high rates of firm nodules in the perioral region and recommends avoiding it there. Hyaluronic acid is preferred in the lips.

What should I do if I feel firmness after treatment? Asymptomatic, invisible firmness often softens over time. But if a lump grows, reddens, becomes painful or turns visible, see your doctor; ultrasound helps in the assessment.

Appointments and information

Whether calcium hydroxyapatite is the right product for you — and whether a hyaluronic acid filler would suit you better — can only be determined by examination. At the Dr. Canan Demir clinic, product choice follows an assessment of skin thickness, tissue support, the area being targeted and your previous treatment history. When a product cannot be dissolved, that assessment matters all the more.

For an individual assessment or an appointment, contact the Dr. Canan Demir clinic. Let's talk through which product actually suits you.

This content is for information only and does not replace medical advice. Treatment decisions are made after a clinical examination.

Sources: Tonnard P, Verpaele A, Romero A. Clarification of the Concept of "Regeneration" in the Context of Calcium Hydroxylapatite and Its Promotion in Regenerative Aesthetics. Aesthetic Surgery Journal. 2026;46(1):NP5-NP7. DOI: 10.1093/asj/sjaf181 — Sukmanskaya N, Cotofana S, Alfertshofer M. Complications of Hyaluronic Acid and Calcium Hydroxylapatite Fillers — A Comprehensive Narrative Review of Clinical Presentation and Current Management Strategies. Journal of Cosmetic Dermatology. 2026;25(8). DOI: 10.1111/jocd.71104 — Meçani R, Amiri M, Kadouch J, et al. Combined and Hybrid Treatments of Hyaluronic Acid (HA) and Calcium Hydroxylapatite (CaHA): A Systematic Review. Aesthetic Plastic Surgery. 2025;49(19):5292-5313. DOI: 10.1007/s00266-025-04904-x — Bravo BSF, Bravo LG, Gouvea BF, et al. Calcium Hydroxylapatite-Based Fillers in Facial Rejuvenation: A Prospective, Single-Center, Unblinded Comparative Outcome Study. Journal of Clinical Medicine. 2025;14(12):4072. DOI: 10.3390/jcm14124072